The important announcements for Hong Kong stocks yesterday are as follows:

Results Express

$PETROCHINA (00857.HK)$: Revenue in 2023 was 3011,012 billion yuan, down 7.04% year on year; net profit was 161,144 billion yuan, up 8.34% year on year.

In 2023, the domestic oil and gas business achieved crude oil production of 774 million barrels, an increase of 0.8% over the previous year; the overseas oil and gas business achieved crude oil production of 163 million barrels, an increase of 17.7% over the previous year.

$KUNLUN ENERGY (00135.HK)$: 2023 revenue of 177.354 billion yuan, up 3.15% year on year; net profit of 5.682 billion yuan, up 8.68% year on year.

$CH OVS G OCEANS (00081.HK)$: 2023 revenue of $56.408 billion, a year-on-year decrease of 1.89%; net profit of 2.302 billion yuan, a year-on-year decrease of 26.94%.

$SINOFERT (00297.HK)$: 2023 turnover of 21.728 billion yuan, a year-on-year decrease of 5.54%; net profit of 626 million yuan, a year-on-year decrease of 43.96%.

$LEAPMOTOR (09863.HK)$: Revenue in 2023 was 16.747 billion yuan, up 35.22% year on year; net loss was 4.216 billion yuan, gross profit changed to 80.47 million yuan year on year, and R&D expenditure was 1.92 billion yuan, up 36.09% year on year.

In 2023, Zero Sports achieved annual delivery of 144,200 new energy vehicles, an increase of 29.7% over the previous year.

$A-LIVING (03319.HK)$: 2023 revenue of 15.443 billion yuan, up 0.42% year on year; net profit of 461 million yuan, down 74.95% year on year.

$ANALOGUE HLDGS (01977.HK)$: Revenue of HK$6.133 billion in 2023, a year-on-year decrease of 5.28%; net profit of HK$252 million, an increase of 119.54% year-on-year.

$GD LAND (00124.HK)$: Revenue of HK$3,877 billion in 2023, up 181.4% year on year, and loss of HK$2,445 billion, changing from profit to loss year over year. Mainly due to the calculation of inventory impairment provisions.

$BAIRONG-W (06608.HK)$: Revenue of 2023 was 2,681 billion yuan, up 30.51% year on year; net profit was 340 million yuan, up 42.06% year on year.

$WUXI XDC (02268.HK)$: Revenue of 2023 was 2.124 billion yuan, up 114.4% year on year; net profit was 284 million yuan, up 82.1% year on year.

$MEDLIVE (02192.HK)$: Revenue in 2023 was about 412 million yuan, up 31.2% year on year; net profit was 242 million yuan, up 106.5% year on year.

$CHINASOUTHCITY (01668.HK)$: The estimated after-tax loss for fiscal year 2023 is approximately HK$4 billion to HK$5 billion.

$JINGRUI HLDGS (01862.HK)$: The net loss is expected to be between RMB 1.7 billion and RMB 2 billion in 2023.

Company news

$SSY GROUP (02005.HK)$: Simeglutide injection has been approved in clinical trials for the use of overweight/obesity. This product belongs to the Chinese Pharmaceutical Registration Classification Class 2.2. Currently, there are no chemically synthesized simeglutide products on the market in the world, which has great clinical development value; dapagliflozin has been approved by the China National Drug Administration and registered as an active ingredient for use in marketed formulations. Mainly used to treat type 2 diabetes and chronic kidney disease.

$ZYLOXTB-B (02190.HK)$: The self-developed Tsuqiao Kirin blood flow guide device has been approved for marketing by the State Drug Administration. It is a revolutionary product for treating intracranial aneurysms. In recent years, it has gradually become one of the important treatments for intracranial aneurysms, especially large or very large aneurysms.

It is estimated that there are more than 150,000 cases of aneurysm in China every year. The number of interventional procedures for intracranial aneurysms in China will reach 440,000 in 2030, with a compound growth rate of 19.9% from 2019 to 2030.

$SANXUN GROUP (06611.HK)$: The cumulative contract sales amount for the first 2 months was about 78 million yuan, a year-on-year decrease of 74.51%.

Buyback News

$BAIRONG-W (06608.HK)$: The total amount of shares to be purchased on the open market is not more than HK$250 million.

$TENCENT (00700.HK)$: It cost HK$1,001 billion to repurchase 3.47 million shares at a repurchase price of HK$285.6-290.2 per share.

$AIA (01299.HK)$: A repurchase of 5.27 million shares was spent at HK$291 million, at a repurchase price of HK$54.75-55.6.

$HSBC HOLDINGS (00005.HK)$: Approximately HK$254 million was spent to repurchase 4.167,600 shares at a repurchase price of HK$60.5-61.4.

$KUAISHOU-W (01024.HK)$: Approximately HK$39,9403 million was spent to repurchase 820,000 shares at a repurchase price of HK$48.15-48.95.

$CK ASSET (01113.HK)$: Spend HK$143.34 million to repurchase 440,000 shares at a repurchase price of HK$32.5-32.6.

Editor/Somer